$MOH
MOLINA HEALTHCARE, INC.

2022 Q4 Form 10-Q Financial Statement

#000117992922000172 Filed on October 27, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3
Revenue $8.223B $7.927B
YoY Change 10.99% 12.6%
Cost Of Revenue $6.992B $6.748B
YoY Change 9.9% 11.56%
Gross Profit $1.231B $1.179B
YoY Change 17.57% 18.97%
Gross Profit Margin 14.97% 14.87%
Selling, General & Admin $856.0M $783.0M
YoY Change 8.35% 6.39%
% of Gross Profit 69.54% 66.41%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $47.00M $45.00M
YoY Change 34.29% 40.63%
% of Gross Profit 3.82% 3.82%
Operating Expenses $903.0M $828.0M
YoY Change 9.45% 7.81%
Operating Profit $328.0M $335.0M
YoY Change 47.75% 51.58%
Interest Expense -$27.00M $28.00M
YoY Change -10.0% -6.67%
% of Operating Profit -8.23% 8.36%
Other Income/Expense, Net -$28.00M
YoY Change -6.67%
Pretax Income $78.00M $307.0M
YoY Change -42.65% 60.73%
Income Tax $22.00M $77.00M
% Of Pretax Income 28.21% 25.08%
Net Earnings $56.00M $230.0M
YoY Change -45.63% 60.84%
Net Earnings / Revenue 0.68% 2.9%
Basic Earnings Per Share $4.00
Diluted Earnings Per Share $0.96 $3.95
COMMON SHARES
Basic Shares Outstanding 58.40M shares 58.10M shares
Diluted Shares Outstanding 58.30M shares

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.505B $7.881B
YoY Change -1.77% 8.6%
Cash & Equivalents $4.006B $4.242B
Short-Term Investments $3.499B $3.639B
Other Short-Term Assets $277.0M $391.0M
YoY Change 12.15% 98.48%
Inventory
Prepaid Expenses
Receivables $2.302B $2.220B
Other Receivables $0.00 $0.00
Total Short-Term Assets $10.08B $10.49B
YoY Change 0.2% 12.02%
LONG-TERM ASSETS
Property, Plant & Equipment $259.0M $412.0M
YoY Change -34.6% 7.01%
Goodwill $1.115B
YoY Change 13.54%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $123.0M $186.0M
YoY Change -31.28% 45.31%
Total Long-Term Assets $2.230B $2.301B
YoY Change 3.96% 38.03%
TOTAL ASSETS
Total Short-Term Assets $10.08B $10.49B
Total Long-Term Assets $2.230B $2.301B
Total Assets $12.31B $12.79B
YoY Change 0.86% 15.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $889.0M $818.0M
YoY Change 5.58% 2.63%
Accrued Expenses
YoY Change
Deferred Revenue $359.0M $663.0M
YoY Change -2.97% 66200.0%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.855B $7.242B
YoY Change -2.72% 19.31%
LONG-TERM LIABILITIES
Long-Term Debt $2.176B $2.175B
YoY Change 0.14% 2.11%
Other Long-Term Liabilities $104.0M $118.0M
YoY Change -25.71% 24.21%
Total Long-Term Liabilities $2.280B $2.293B
YoY Change -1.43% 3.06%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.855B $7.242B
Total Long-Term Liabilities $2.280B $2.293B
Total Liabilities $9.350B $9.752B
YoY Change -2.39% 14.53%
SHAREHOLDERS EQUITY
Retained Earnings $2.796B $2.937B
YoY Change 16.55% 27.92%
Common Stock $328.0M $289.0M
YoY Change 38.98% 40.98%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.964B $3.041B
YoY Change
Total Liabilities & Shareholders Equity $12.31B $12.79B
YoY Change 0.86% 15.95%

Cashflow Statement

Concept 2022 Q4 2022 Q3
OPERATING ACTIVITIES
Net Income $56.00M $230.0M
YoY Change -45.63% 60.84%
Depreciation, Depletion And Amortization $47.00M $45.00M
YoY Change 34.29% 40.63%
Cash From Operating Activities -$212.0M $254.0M
YoY Change -135.51% -44.9%
INVESTING ACTIVITIES
Capital Expenditures $10.00M -$31.00M
YoY Change -147.62% 14.81%
Acquisitions
YoY Change
Other Investing Activities $158.0M -$316.0M
YoY Change -130.04% -52.91%
Cash From Investing Activities $148.0M -$347.0M
YoY Change -127.06% -50.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -183.0M 10.00M
YoY Change -971.43% -350.0%
NET CHANGE
Cash From Operating Activities -212.0M 254.0M
Cash From Investing Activities 148.0M -347.0M
Cash From Financing Activities -183.0M 10.00M
Net Change In Cash -247.0M -83.00M
YoY Change -447.89% -65.56%
FREE CASH FLOW
Cash From Operating Activities -$212.0M $254.0M
Capital Expenditures $10.00M -$31.00M
Free Cash Flow -$222.0M $285.0M
YoY Change -135.92% -41.6%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001179929
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2022Q3 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
0 usd
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
0 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
0 usd
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
0 usd
CY2021Q3 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
0 usd
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
0 usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-31719
dei Entity Registrant Name
EntityRegistrantName
MOLINA HEALTHCARE, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
13-4204626
dei Entity Address Address Line1
EntityAddressAddressLine1
200 Oceangate
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
dei Entity Address City Or Town
EntityAddressCityOrTown
Long Beach,
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
90802
dei City Area Code
CityAreaCode
562
dei Local Phone Number
LocalPhoneNumber
435-3666
dei Security12b Title
Security12bTitle
Common Stock, $0.001 Par Value
dei Trading Symbol
TradingSymbol
MOH
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
58400000 shares
CY2022Q3 us-gaap Premiums Earned Net
PremiumsEarnedNet
7636000000 usd
CY2021Q3 us-gaap Premiums Earned Net
PremiumsEarnedNet
6800000000 usd
us-gaap Premiums Earned Net
PremiumsEarnedNet
22966000000 usd
us-gaap Premiums Earned Net
PremiumsEarnedNet
19689000000 usd
CY2022Q3 moh Health Care Organization Premium Tax Revenue
HealthCareOrganizationPremiumTaxRevenue
223000000 usd
CY2021Q3 moh Health Care Organization Premium Tax Revenue
HealthCareOrganizationPremiumTaxRevenue
204000000 usd
moh Health Care Organization Premium Tax Revenue
HealthCareOrganizationPremiumTaxRevenue
646000000 usd
moh Health Care Organization Premium Tax Revenue
HealthCareOrganizationPremiumTaxRevenue
576000000 usd
CY2022Q3 us-gaap Net Investment Income
NetInvestmentIncome
49000000 usd
CY2021Q3 us-gaap Net Investment Income
NetInvestmentIncome
20000000 usd
us-gaap Net Investment Income
NetInvestmentIncome
82000000 usd
us-gaap Net Investment Income
NetInvestmentIncome
39000000 usd
CY2022Q3 us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
19000000 usd
CY2021Q3 us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
16000000 usd
us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
57000000 usd
us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
58000000 usd
CY2022Q3 us-gaap Revenues
Revenues
7927000000 usd
CY2021Q3 us-gaap Revenues
Revenues
7040000000 usd
us-gaap Revenues
Revenues
23751000000 usd
us-gaap Revenues
Revenues
20362000000 usd
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6748000000 usd
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6049000000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
20183000000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
17342000000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
560000000 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
532000000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1682000000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1489000000 usd
CY2022Q3 moh Premium Tax Expenses
PremiumTaxExpenses
223000000 usd
CY2021Q3 moh Premium Tax Expenses
PremiumTaxExpenses
204000000 usd
moh Premium Tax Expenses
PremiumTaxExpenses
646000000 usd
moh Premium Tax Expenses
PremiumTaxExpenses
576000000 usd
CY2022Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
45000000 usd
CY2021Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
32000000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
129000000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
96000000 usd
CY2022Q3 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
16000000 usd
CY2021Q3 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
2000000 usd
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
43000000 usd
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
30000000 usd
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
7592000000 usd
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
6819000000 usd
us-gaap Costs And Expenses
CostsAndExpenses
22683000000 usd
us-gaap Costs And Expenses
CostsAndExpenses
19533000000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
335000000 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
221000000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
1068000000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
829000000 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
28000000 usd
CY2021Q3 us-gaap Interest Expense
InterestExpense
30000000 usd
us-gaap Interest Expense
InterestExpense
83000000 usd
us-gaap Interest Expense
InterestExpense
90000000 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-28000000 usd
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-30000000 usd
CY2021Q3 moh Health Plan Contract Term
HealthPlanContractTerm
P4Y
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-83000000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-90000000 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
307000000 usd
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
191000000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
985000000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
739000000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
77000000 usd
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
48000000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
249000000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
183000000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
230000000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
143000000 usd
us-gaap Net Income Loss
NetIncomeLoss
736000000 usd
us-gaap Net Income Loss
NetIncomeLoss
556000000 usd
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.00
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.49
CY2021Q3 moh Health Plan Extension Option Period
HealthPlanExtensionOptionPeriod
P2Y
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
12.74
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
9.63
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.95
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.46
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
12.58
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
9.51
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
230000000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
143000000 usd
us-gaap Net Income Loss
NetIncomeLoss
736000000 usd
us-gaap Net Income Loss
NetIncomeLoss
556000000 usd
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-75000000 usd
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-13000000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-237000000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-27000000 usd
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-18000000 usd
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-4000000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-57000000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-7000000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-57000000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-9000000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-180000000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-20000000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
173000000 usd
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
134000000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
556000000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
536000000 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4242000000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4438000000 usd
CY2022Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
3639000000 usd
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
3202000000 usd
CY2022Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
2220000000 usd
CY2021Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
2177000000 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
391000000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
247000000 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
10492000000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
10064000000 usd
CY2022Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
412000000 usd
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
396000000 usd
CY2022Q3 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
1263000000 usd
CY2021Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
1252000000 usd
CY2022Q3 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
242000000 usd
CY2021Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
212000000 usd
CY2022Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
198000000 usd
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
106000000 usd
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
186000000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
179000000 usd
CY2022Q3 us-gaap Assets
Assets
12793000000 usd
CY2021Q4 us-gaap Assets
Assets
12209000000 usd
CY2022Q3 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
3622000000 usd
CY2021Q4 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
3363000000 usd
CY2022Q3 moh Medical Premium Liability Due To Agency
MedicalPremiumLiabilityDueToAgency
2139000000 usd
CY2021Q4 moh Medical Premium Liability Due To Agency
MedicalPremiumLiabilityDueToAgency
2472000000 usd
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
818000000 usd
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
842000000 usd
CY2022Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
663000000 usd
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
370000000 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
7242000000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7047000000 usd
CY2022Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2175000000 usd
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2173000000 usd
CY2022Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
217000000 usd
CY2021Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
219000000 usd
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
118000000 usd
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
140000000 usd
CY2022Q3 us-gaap Liabilities
Liabilities
9752000000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
9579000000 usd
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58000000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58000000 shares
CY2022Q3 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
0 usd
CY2021Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
0 usd
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
289000000 usd
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
236000000 usd
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-185000000 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5000000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
2937000000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
2399000000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
3041000000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
2630000000 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12793000000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12209000000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
2630000000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
258000000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-76000000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-18000000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
2794000000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
248000000 usd
CY2022Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
200000000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-47000000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
35000000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
2830000000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
230000000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-57000000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
38000000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
3041000000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
2096000000 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
228000000 usd
CY2021Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
122000000 usd
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-11000000 usd
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-27000000 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
2164000000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
185000000 usd
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
21000000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
2370000000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
143000000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-9000000 usd
CY2021Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
14000000 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
2518000000 usd
us-gaap Net Income Loss
NetIncomeLoss
736000000 usd
us-gaap Net Income Loss
NetIncomeLoss
556000000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
129000000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
96000000 usd
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
35000000 usd
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
8000000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
80000000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
49000000 usd
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-3000000 usd
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
9000000 usd
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
15000000 usd
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
247000000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
110000000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
43000000 usd
us-gaap Increase Decrease In Health Care Insurance Liabilities
IncreaseDecreaseInHealthCareInsuranceLiabilities
251000000 usd
us-gaap Increase Decrease In Health Care Insurance Liabilities
IncreaseDecreaseInHealthCareInsuranceLiabilities
522000000 usd
moh Increase Decrease In Medical Premium Liability Due To Agency
IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency
-360000000 usd
moh Increase Decrease In Medical Premium Liability Due To Agency
IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency
810000000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-40000000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
129000000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
293000000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-374000000 usd
CY2022Q3 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Receivable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable
94000000 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
59000000 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
23000000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
985000000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1522000000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
1764000000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
2018000000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
1082000000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
965000000 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
134000000 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
81000000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
56000000 usd
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
41000000 usd
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-3000000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-938000000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1106000000 usd
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
4 segment
CY2022Q3 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Net Payable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable
85000000 usd
moh Common Stock Withheld To Settle Employee Tax Obligations
CommonStockWithheldToSettleEmployeeTaxObligations
53000000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
200000000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
128000000 usd
moh Common Stock Withheld To Settle Employee Tax Obligations
CommonStockWithheldToSettleEmployeeTaxObligations
52000000 usd
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
20000000 usd
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
20000000 usd
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
15000000 usd
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-4000000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-258000000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-204000000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-211000000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
212000000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4506000000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4223000000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4295000000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4435000000 usd
us-gaap Use Of Estimates
UseOfEstimates
Use of EstimatesThe preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4242000000 usd
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4357000000 usd
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
53000000 usd
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
78000000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4295000000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4435000000 usd
CY2022Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
2220000000 usd
CY2021Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
2177000000 usd
CY2022Q3 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Payable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable
179000000 usd
CY2022Q3 moh Medical Premiums Liability Medical Care Costs Threshold
MedicalPremiumsLiabilityMedicalCareCostsThreshold
1091000000 usd
CY2021Q4 moh Medical Premiums Liability Medical Care Costs Threshold
MedicalPremiumsLiabilityMedicalCareCostsThreshold
1016000000 usd
CY2022Q3 moh Amounts Due To Government Agencies Medicaid Other
AmountsDueToGovernmentAgenciesMedicaidOther
617000000 usd
CY2021Q4 moh Amounts Due To Government Agencies Medicaid Other
AmountsDueToGovernmentAgenciesMedicaidOther
263000000 usd
CY2022Q3 moh Amounts Due To Government Agencies Medicare Medical Loss Ratio And Profit Sharing Threshold
AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold
100000000 usd
CY2021Q4 moh Amounts Due To Government Agencies Medicare Medical Loss Ratio And Profit Sharing Threshold
AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold
101000000 usd
CY2022Q3 moh Amounts Due To Government Agencies Risk Adjustment And Part D Risk Sharing
AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing
74000000 usd
CY2021Q4 moh Amounts Due To Government Agencies Risk Adjustment And Part D Risk Sharing
AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing
89000000 usd
CY2022Q3 moh Other Medicare Program
OtherMedicareProgram
23000000 usd
CY2021Q4 moh Other Medicare Program
OtherMedicareProgram
35000000 usd
CY2022Q3 moh Amounts Dueto Government Agencies Risk Adjustment
AmountsDuetoGovernmentAgenciesRiskAdjustment
179000000 usd
CY2021Q4 moh Amounts Dueto Government Agencies Risk Adjustment
AmountsDuetoGovernmentAgenciesRiskAdjustment
902000000 usd
CY2022Q3 moh Amounts Due To Government Agencies Marketplace Medical Loss Ratio Threshold
AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold
4000000 usd
CY2021Q4 moh Amounts Due To Government Agencies Marketplace Medical Loss Ratio Threshold
AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold
18000000 usd
CY2022Q3 moh Amounts Dueto Government Agencies Other
AmountsDuetoGovernmentAgenciesOther
51000000 usd
CY2021Q4 moh Amounts Dueto Government Agencies Other
AmountsDuetoGovernmentAgenciesOther
48000000 usd
CY2022Q3 moh Medical Premium Liability Due To Agency
MedicalPremiumLiabilityDueToAgency
2139000000 usd
CY2021Q4 moh Medical Premium Liability Due To Agency
MedicalPremiumLiabilityDueToAgency
2472000000 usd
CY2021Q4 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Payable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable
902000000 usd
CY2021Q4 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Receivable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable
7000000 usd
CY2021Q4 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Net Payable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable
895000000 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, receivables, and restricted investments. Our investments and a portion of our cash equivalents are managed by professional portfolio managers operating under documented investment guidelines. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels. Our investments consist primarily of investment-grade debt securities with final maturities of less than 15 years, or less than 15 years average life for structured securities. Restricted investments are invested principally in cash, cash equivalents, and U.S. Treasury securities. Concentration of credit risk with respect to accounts receivable is limited because our payors consist principally of the federal government, and governments of each state in which our health plan subsidiaries operate.</span></div>
moh Investments Maturity Period
InvestmentsMaturityPeriod
P15Y
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
230000000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
143000000 usd
us-gaap Net Income Loss
NetIncomeLoss
736000000 usd
us-gaap Net Income Loss
NetIncomeLoss
556000000 usd
CY2022Q2 moh Shares Outstanding Excluding Restricted Stock Awards
SharesOutstandingExcludingRestrictedStockAwards
57600000 shares
CY2021Q2 moh Shares Outstanding Excluding Restricted Stock Awards
SharesOutstandingExcludingRestrictedStockAwards
57800000 shares
CY2021Q4 moh Shares Outstanding Excluding Restricted Stock Awards
SharesOutstandingExcludingRestrictedStockAwards
57900000 shares
CY2020Q4 moh Shares Outstanding Excluding Restricted Stock Awards
SharesOutstandingExcludingRestrictedStockAwards
58000000.0 shares
CY2022Q3 moh Weighted Average Numberof Shares Share Based Compensation
WeightedAverageNumberofSharesShareBasedCompensation
0 shares
CY2021Q3 moh Weighted Average Numberof Shares Share Based Compensation
WeightedAverageNumberofSharesShareBasedCompensation
0 shares
moh Weighted Average Numberof Shares Share Based Compensation
WeightedAverageNumberofSharesShareBasedCompensation
200000 shares
moh Weighted Average Numberof Shares Share Based Compensation
WeightedAverageNumberofSharesShareBasedCompensation
300000 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0 shares
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
300000 shares
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
500000 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57600000 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57800000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57800000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57800000 shares
CY2022Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
700000 shares
CY2021Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
700000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
700000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
700000 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58300000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58500000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58500000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58500000 shares
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.00
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.49
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
12.74
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
9.63
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.95
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.46
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
12.58
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
9.51
us-gaap Gain Loss On Fair Value Hedges Recognized In Earnings
GainLossOnFairValueHedgesRecognizedInEarnings
-4000000 usd
us-gaap Gain Loss On Fair Value Hedges Recognized In Earnings
GainLossOnFairValueHedgesRecognizedInEarnings
-3000000 usd
CY2022Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
3639000000 usd
CY2022Q3 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
8000000 usd
CY2022Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
8000000 usd
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
3202000000 usd
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
47000000 usd
CY2021Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
47000000 usd
us-gaap Gain Loss On Fair Value Hedges Recognized In Earnings
GainLossOnFairValueHedgesRecognizedInEarnings
-4000000 usd
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
20000000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
3882000000 usd
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
243000000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
3639000000 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
3208000000 usd
CY2021Q3 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
6000000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
12000000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
18000000 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
3202000000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
378000000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
374000000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
2330000000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
2186000000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost
390000000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
364000000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities After Ten Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost
784000000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities After Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
715000000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
3882000000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
3639000000 usd
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
7000000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
2815000000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
163000000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
1457 position
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
708000000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
80000000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
305 position
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
1706000000 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
18000000 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
677 position
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0 security
CY2022Q3 us-gaap Debt Securities Held To Maturity Excluding Accrued Interest Before Allowance For Credit Loss
DebtSecuritiesHeldToMaturityExcludingAccruedInterestBeforeAllowanceForCreditLoss
242000000 usd
CY2022Q3 us-gaap Held To Maturity Securities Debt Maturities Within One Year Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount
201000000 usd
CY2022Q3 us-gaap Held To Maturity Securities Debt Maturities After One Through Five Years Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount
37000000 usd
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
-338000000 usd
CY2022Q3 us-gaap Held To Maturity Securities Debt Maturities After Five Through Ten Years Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount
4000000 usd
us-gaap Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense
ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the details of our medical claims and benefits payable as of the dates indicated:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Claims incurred but not paid (“IBNP”)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,553 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,486 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacy payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">241 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitation payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">738 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">576 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,622 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,363 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div>
CY2022Q3 moh Liabilityfor Unpaid Claimsand Claims Adjustment Expense Incurredbut Not Paid Ibnp Feeforservice Claims Amount
LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount
2553000000 usd
CY2021Q4 moh Liabilityfor Unpaid Claimsand Claims Adjustment Expense Incurredbut Not Paid Ibnp Feeforservice Claims Amount
LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount
2486000000 usd
CY2022Q3 moh Pharmacy Claims Payable
PharmacyClaimsPayable
241000000 usd
CY2021Q4 moh Pharmacy Claims Payable
PharmacyClaimsPayable
219000000 usd
CY2022Q3 moh Capitation Claims Payable
CapitationClaimsPayable
90000000 usd
CY2021Q4 moh Capitation Claims Payable
CapitationClaimsPayable
82000000 usd
CY2022Q3 moh Other Claims Payable
OtherClaimsPayable
738000000 usd
CY2021Q4 moh Other Claims Payable
OtherClaimsPayable
576000000 usd
CY2022Q3 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
3622000000 usd
CY2021Q4 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
3363000000 usd
CY2022Q3 moh Medical Claims And Benefits Payable
MedicalClaimsAndBenefitsPayable
317000000 usd
CY2021Q4 moh Medical Claims And Benefits Payable
MedicalClaimsAndBenefitsPayable
226000000 usd
CY2021Q4 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
3363000000 usd
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
20521000000 usd
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
-338000000 usd
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
20183000000 usd
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
17538000000 usd
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
2481000000 usd
us-gaap Payments For Losses And Loss Adjustment Expense
PaymentsForLossesAndLossAdjustmentExpense
20019000000 usd
moh Liability For Unpaid Claims And Claims Adjustment Expense Business Acquisitions Net Of Post Closing Adjustments
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments
8000000 usd
moh Medical Claims And Benefits Payable Adjustments Change In Provider
MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
87000000 usd
CY2022Q3 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
3622000000 usd
CY2020Q4 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
2696000000 usd
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
17558000000 usd
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
-216000000 usd
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
17342000000 usd
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
14880000000 usd
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
2008000000 usd
us-gaap Payments For Losses And Loss Adjustment Expense
PaymentsForLossesAndLossAdjustmentExpense
16888000000 usd
moh Liability For Unpaid Claims And Claims Adjustment Expense Business Acquisitions Net Of Post Closing Adjustments
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments
-27000000 usd
moh Medical Claims And Benefits Payable Adjustments Change In Provider
MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
68000000 usd
CY2021Q3 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
3191000000 usd
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
-216000000 usd
CY2022Q3 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
25000000 usd
CY2021Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
27000000 usd
CY2022Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2175000000 usd
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2173000000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
985000000 usd
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
4 segment
CY2022Q3 us-gaap Revenues
Revenues
7927000000 usd
CY2021Q3 us-gaap Revenues
Revenues
7040000000 usd
us-gaap Revenues
Revenues
23751000000 usd
us-gaap Revenues
Revenues
20362000000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
335000000 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
221000000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
1068000000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
829000000 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-28000000 usd
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-30000000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-83000000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-90000000 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
307000000 usd
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
191000000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
739000000 usd

Files In Submission

Name View Source Status
0001179929-22-000172-index-headers.html Edgar Link pending
0001179929-22-000172-index.html Edgar Link pending
0001179929-22-000172.txt Edgar Link pending
0001179929-22-000172-xbrl.zip Edgar Link pending
exhibit101_changexreques.htm Edgar Link pending
exhibit101_changexreques001.jpg Edgar Link pending
exhibit101_changexreques002.jpg Edgar Link pending
exhibit101_changexreques003.jpg Edgar Link pending
exhibit101_changexreques004.jpg Edgar Link pending
exhibit101_changexreques005.jpg Edgar Link pending
exhibit101_changexreques006.jpg Edgar Link pending
exhibit101_changexreques007.jpg Edgar Link pending
exhibit101_changexreques008.jpg Edgar Link pending
exhibit101_changexreques009.jpg Edgar Link pending
exhibit101_changexreques010.jpg Edgar Link pending
exhibit101_changexreques011.jpg Edgar Link pending
exhibit101_changexreques012.jpg Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
moh-20220930.htm Edgar Link pending
moh-20220930.xsd Edgar Link pending
moh-20220930_g1.jpg Edgar Link pending
moh-20220930_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
moh-20220930_def.xml Edgar Link unprocessable
moh-20220930_pre.xml Edgar Link unprocessable
moh3q22_ex311.htm Edgar Link pending
moh3q22_ex312.htm Edgar Link pending
moh3q22_ex321.htm Edgar Link pending
moh3q22_ex322.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
moh-20220930_lab.xml Edgar Link unprocessable
moh-20220930_htm.xml Edgar Link completed